Below you will find information and documents related to the Corporate Governance of IBT AB.
Annual General Meeting 2017
Press Release AGM English
Information in English
Proxy form AGM
Proposal for Board Mandate Item 16
Information in Swedish
IBT kallelse AGM
Forslag till bemyndigande Punkt 16
Fullstandigt forslag till optionsprogram punkt 17
Bilaga A Punkt 17
Nominating Committee for the Annual General Meeting
The Nominating Committee of Infant Bacterial Therapeutics AB was established by decision of the Board of Directors, and consists of the Chairman of Infant Bacterial Therapeutics AB, Peter Rothschild, together with Per-Erik Andersson, representing Annwall & Rothschild Investment AB, the company’s largest shareholder, Sebastian Jahreskog, the company’s second largest shareholder, and Jannis Kitsakis, representing the company’s third largest shareholder Fjärde AP-Fonden.
Three members of the Nominating Committee are independent in relation to the company and its management.
The Nominating Committee shall prepare recommendations for the following matters to be put before the 2017 AGM for resolution:
- a) appointment of the Chairman of the AGM
- b) election of the Board of Directors
- c) election of the Board Chairman
- d) election of auditors
- e) fees for members of the Board
- f) fees for the auditors
- g) appointment of the Nominating Committee ahead of the 2018 AGM.
Contact: Per-Erik Andersson
Articles of Association
Articles of association for Infant Bacterial Therapeutics AB is available below in Swedish and English:
IBT – Bolagsordning / Articles of Association
Corporate Governance Report
Corporate Governance Report for Infant Bacterial Therapeutics AB is available below in Swedish and English:
IBT – Corp. Gov. Report 2017
IBT – Bolagsstyrningsrapport 2017